(Breast Cancer) Is Tecentriq + Chemotherapy Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- March 16, 2022
- Read time: 1 minute
On February 16, 2022, L. Gianni et al. of Fondazione Michelangelo published in the medical journal Annals of Oncology the efficacy and safety results of Tecentriq (Atezolizumab) plus chemotherapy as neoadjuvant chemotherapy in high-risk locally advanced triple-negative breast cancer patients in the NeoTRIPaPDL1 Phase 3 clinical trial.
NeoTRIPaPDL1 was a multicenter Phase 3 clinical trial that randomized high-risk locally advanced triple-negative breast cancer patients (N=280) to either the Tecentriq group (8 cycles of 3-week intervals, Day 1: Tecentriq 1200 mg, Days 1 and 8: chemotherapy, N=138) or the chemotherapy group (8 cycles of 3-week intervals, Days 1 and 8: chemotherapy, N=142). The primary endpoint was event-free survival, and the secondary endpoint was pathologic complete response rate.
Trial results showed that pathologic complete response rates were: Tecentriq group 48.6% / chemotherapy group 44.4%, with no significant difference.
Regarding safety, adverse event rates were similar between the two groups. The most commonly observed adverse event in the Tecentriq group was elevated liver transaminases, and the incidence of serious adverse events was higher in the Tecentriq group.
Based on the NeoTRIPaPDL1 trial results, L. Gianni et al. concluded that in high-risk locally advanced triple-negative breast cancer patients using Tecentriq plus chemotherapy as neoadjuvant chemotherapy, pathologic complete response rate did not show significant improvement. Data tracking for event-free survival is ongoing.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4